|1.||Hoeflich, Klaus P: 2 articles (05/2013 - 11/2012)|
|2.||Jubb, Adrian M: 2 articles (05/2013 - 11/2012)|
|3.||Pitts, Todd M: 2 articles (01/2013 - 01/2013)|
|4.||Murray, Brion W: 2 articles (01/2013 - 05/2010)|
|5.||Tan, Aik-Choon: 2 articles (01/2013 - 01/2013)|
|6.||Eckhardt, S Gail: 2 articles (01/2013 - 01/2013)|
|7.||Shin, Eun-Young: 1 article (05/2015)|
|8.||Han, Sang-Bae: 1 article (05/2015)|
|9.||Chung, Jin H: 1 article (05/2015)|
|10.||You, Soon-Tae: 1 article (05/2015)|
05/18/2010 - "In tumor models, PF-3758309 inhibits PAK4-dependent pathways in proteomic studies and regulates functional activities related to cell proliferation and survival. "
11/15/2012 - "Treatment of Kras(G12D) mice with either of two distinct small molecule Pak inhibitors (PF3758309 and FRAX597) caused tumor regression and loss of Erk and Akt activity. "
01/01/2010 - "Experiments using PF-3758309 confirm that inhibiting PAK is a beneficial strategy to combat some tumors, and this activity is likely related to modulation of both cell proliferation and survival. "
05/18/2010 - "PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC(50) value of 0.4 nM in the most sensitive model. "
05/18/2010 - "Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth."
|2.||Colorectal Neoplasms (Colorectal Cancer)
|3.||Sarcoma (Soft Tissue Sarcoma)
05/01/2015 - "Consistent with this result, PAK4 inhibition by PF3758309, a potent ATP-competitive inhibitor of PAKs, suppressed not only α-MSH-induced melanogenesis in B16 melanoma and human epithelial melanocyte cells but also UVB-induced melanogenesis in the skin of melanin-possessing hairless mice (HRM-2) in a dose-dependent manner. "
|5.||Melanoma (Melanoma, Malignant)
05/01/2013 - "PAK1 was inhibited in vitro and in vivo using RNA interference or PF-3758309 inhibitor treatment in a panel of melanoma cell lines with known BRAF and RAS (rat sarcoma) genotype to better understand its role in melanoma cell proliferation and migration. "
05/01/2013 - "Treatment of BRAF wild-type melanomas with PF-3758309 PAK inhibitor decreased tumor growth for SK-MEL23 and 537MEL xenografts (91% and 63% inhibition, respectively; P < .001) and MAPK pathway activation in vivo. "
|3.||Histone Deacetylase Inhibitors
|4.||Propolis (Bee Bread)
|5.||Melanocyte-Stimulating Hormones (MSH)
|7.||Adenosine Triphosphate (ATP)
|10.||caffeic acid phenethyl ester
|1.||Heterologous Transplantation (Xenotransplantation)